The efficiency of the intravenous laser therapy in patients with hypothyroidism combined with nonalcoholic fatty liver disease
Abstract
To asses the efficiency of intravenous laser therapy (IVLT) in the treatment of patients with hypothyroidism combined with nonalcoholic fatty liver disease was studied 180 people with dyslipidemia. The I group included 60 patients who didn’t have any complaints, but had dyslipidemia. The II group included 60 patients with nonalcoholic fatty liver disease, the III group included 60 patients with hypothyroidism combined with nonalcoholic fatty liver disease. Based on the genetic research polymorphic variants of gene CYP7A1 patients were divided into subgroups: I AA — 52 people, I CC — 8 people; II AA — 50 people, II CC — 10 people; III AA — 48 people, III CC — 12 people. Treatment was conducted by Omega-3 acid ethyl esterscapsules and by IVLT with a radiation wavelength of 635 nm and the power of1,5 mW (device “Lazmik”).
A lipid profile of the blood was tested to determine total cholesterol, triglycerides, low-density lipoproteins, high-density lipoproteins, and an atherogenic index. To assess the functional state of the liver, the parameters of biochemical hepatic samples and sonographic dynamics of structural changes were studied..
Statistical processing of the results of the study was carried out using the software «Statistica 10».
The most pronounced effect was achieved in II CC and III CC groups by reducing the levels of total cholesterol, low density lipoproteins, triglycerides and atherogenic index. Patients of II AA and III AA groups had the fastest increase dynamics of high density lipoproteins level. Given the fact that the most atherogenic lipid profile at the time of enrollment in the study observed in genotype CC in groups II and III, the resulting dynamics demonstrated the significant impact of laser radiation on the functional activity of hepatocytes. The dynamics of normalization of cytolysis syndrome wasn’t caused by genetic differences and prevailed in group II compared to group III, in which the presence of hormonal imbalance prevented activation of reparative mechanisms of damaged liver cells.
Downloads
References
Баракаев Б.Р. Морфологическая оценка превентивного и лечебного действия низкоинтенсивного лазерного излучения на течение острого токсического гепатита / Б.Р.Баракаев, Г.К.Мироджов, З.Г.Мишанина // Архив патологии. – 1989. – Т. 51, № 12.- С. 28-32.
Визир В.А. Ультразвуковая диагностика в практике врача-терапевта / В.А.Визир, И.Б.Приходько. – Винница : Нова книга, 2007. – 400 с.
Ворожейкин В.М. Структура нормальной и патологически измененной печени после воздействия низкоинтенсивного лазерного излучения в инфракрасном диапазоне // Новые достижения лазерной медицины. – М. – С.– Пб., 1993. – С.262-263.
Гамалея Н.Ф. Лазеры в эксперименте и клинике. – М. : Медицина, 1972. – 232 с.
Гейниц А.В. Внутривенное лазерное облучение крови / А.В.Гейниц, С.В.Москвин, А.А.Ачилов. – М. – Тверь : ООО Триада, 2012. – 336 с.
Емельянов Д.Н. Влияние внутривенного лазерного облучения крови на общую активность церулоплазмина у больных хроническими диффузными заболеваниями печени / Д.Н.Емельянов, В.В.Скворцов, Р.Г.Мязин // Гепатология. – 2004. – №3. – С. 37-39.
Зубкова С.М. Всесоюзная конференция по применению методов и средств лазерной техники в биологии и медицине / С.М.Зубкова, И.Н.Данилова, Т.М.Каменецкая // Вопросы курортологии, физиотерапии и лечебной физкультуры. – 1980. – № 6. – С. 66-67.
Идрисова Р.С. Влияние монохроматического красного света на репарацию печени в эксперименте и клинике // Здравоохранение Казахстана. – 1977. – № 2.– С. 57-59.
Илларионов В.Е. Основы лазерной терапии.– М. : Респект, 1992. – 124 с.
Илларионов В.Е. Современные методы физиотерапии : Руководство для врачей общей практики (семейных врачей) / В.Е.Илларионов, В.Б.Симоненко. – М. : Медицина, 2007. – 176 с.
Корочкин И.М. Механизмы терапевтической эффективности излучения гелий-неонового лазера / И.М.Корочкин, Е.В.Бабенко // Советская медицина. – 1990. – № 3. – С. 3-8.
De Castro-Oros I. Promoter variant -204A >C of the cholesterol 7alpha-hydroxylase gene: association with response to plant sterols in humans and increased transcriptional activity in transfected HepG2 cells / I. De Castro-Oros, S.Pampin, M.Cofan // Clin. Nutr. – 2011.– Vol. 30. –P. 239–246.
Hofman M.K. CYP7A1 A-278C Polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. The American Society for Nutritional Sciences // J. Nutr. – 2004. – Vol. 134. – P. 2200–2204.
Pullinger C.R. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype / C.R.Pullinger, C.Eng, G.Salen, S.Shefer // J. Clin. Investig. – 2002. – Vol. 110. – P. 109–117.
Qiang C. Relationship between CYP7A1 -204A>C polymorphism with gallbladder stone disease and serum lipid levels: a meta-analysis // Lipid in Health and Disease. – 2014. – Vol. 13. – P. 126–132.
Shen J. The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate / J.Shen, D.K.Arnett, L.D.Parnell // J. Cardiovasc. Pharmacol. – 2012. – Vol. 59. – P. 254–259.
Stinton L.M. Epidemiology of gallbladder disease: cholelithiasis and cancer / L.M.Stinton, E.A.Shaffer // Gut Liver. – 2012. – Vol.6. – P. 172–187.
